Amneal Pharmaceuticals, Inc. (AMRX)
Nasdaq: AMRX · Pharmaceutical Preparations · filing with the SEC since 2017
Grade5.3
◀ Past 4.9● Present 6.3▶ Future 4.3
Who owns Amneal Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
6
Tushar Patel holds 17.6% of Class A Common Stock, par value $0.01, as its SCHEDULE 13D/A filed Aug 12, 2026 says.
Directors and officers
14
report now, of 30 people on the record since 2018. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Tushar Patel
SCHEDULE 13D/A · filed Aug 12, 2026 · Class A Common Stock, par value $0.01 · 15.7% in Mar 17, 2025
Chintu Patel
SCHEDULE 13D/A · filed Aug 12, 2026 · Class A Common Stock, par value $0.01 · 8.2% in Oct 7, 2025
Chirag Patel
SCHEDULE 13D/A · filed Aug 12, 2026 · Class A Common Stock, par value $0.01 · 7.1% in Aug 8, 2025
Blackrock, Inc.
SCHEDULE 13G · filed Apr 27, 2026 · Common Stock
Akram Mahesh
SCHEDULE 13G/A · filed May 14, 2025 · Class A Common Stock, par value $0.01
Patel Dipan
SCHEDULE 13D/A · filed Mar 26, 2026 · Class A Common Stock, par value $0.01 · 7.6% in Oct 6, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 5.02% in Apr 30, 2025
UBS Group AG
SCHEDULE 13G/A · filed Feb 10, 2025 · Class A Common Stock, par value $0.01 per share · reported falling below 5%, from 6.9% in Oct 30, 2024
What AMRX reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Excluding Affiliated Entity
An entity · consolidated entity · owns, named in the 10-K filed Feb 27, 2026
New PubCo
An entity · legal entity · owns, named in the 10-K filed Feb 27, 2026
Old PubCo
An entity · legal entity · owns, named in the 10-K filed Feb 27, 2026
AvKARE, LLC and R&S
A company bought · acquisition · owns, named in the 10-K filed Feb 27, 2026
32 subsidiaries in 8 countries, from the list filed with the 10-K filed Feb 27, 2026.
Insider tradesForm 4
7sales
0purchases
0sales on a scheduled plan
5people selling
$9.8Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 40 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Shah Nikita | Executive Vice President | 2 | $4.1M | 0 | 0 | $0 |
| Daly Jason B. | EVP, Chief Legal Officer | 2 | $3.8M | 0 | 0 | $0 |
| Kiely John | director | 1 | $900,000 | 0 | 0 | $0 |
| Nark Ted C | director | 1 | $600,000 | 0 | 0 | $0 |
| Autor Deborah M. | director | 1 | $500,000 | 0 | 0 | $0 |